Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/56188
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZethraeus, Niklasen_US
dc.contributor.authorBorgström, Fredriken_US
dc.contributor.authorJönsson, Bengten_US
dc.contributor.authorKanis, Johnen_US
dc.date.accessioned2012-03-28T13:05:43Z-
dc.date.available2012-03-28T13:05:43Z-
dc.date.issued2004en_US
dc.identifier.urihttp://hdl.handle.net/10419/56188-
dc.description.abstractThe cost-effectiveness of hormone replacement therapy (HRT) based on a societal perspective is reassessed based on new medical evidence found in the Women's Health Initiative (WHI). Within a model framework using an individual state transition model the cost-effectiveness of 50-60 year old women with menopausal symptoms is assessed in Sweden. The Markov model has a 50 year time horizon divided into a cycle length of 1 year. The model consists of the following disease states: Coronary Heart Disease (CHD), Stroke, Venous thromboembolic events, breast cancer, colorectal cancer, hip fracture, vertebral fracture and wrist fracture. An intervention is modelled by its impact on the disease risks during and after the cessation of therapy. The model calculates costs and quality adjusted life years (QALYs) with and without intervention. The resulting cost per gained QALY is compared to the value of a gained QALY, which is set to SEK 600 000. The model requires data on clinical effects, risks, mortality rates, quality of life weights and costs valid for Sweden. The cost-effectiveness ratios are estimated at about SEK 10 000, which is far below the value of a gained QALY. Conditional on that HRT increases the quality of life weight more than 0.013 the therapy is cost-effective. In conclusion, given the new evidence in WHI, there is still a high probability that HRT is a cost-effective strategy for women with menopausal symptoms.en_US
dc.language.isoengen_US
dc.publisher|aEkonomiska Forskningsinst. |cStockholmen_US
dc.relation.ispartofseries|aSSE/EFI Working Paper Series in Economics and Finance |x571en_US
dc.subject.jelD61en_US
dc.subject.jelI10en_US
dc.subject.jelI12en_US
dc.subject.jelI19en_US
dc.subject.ddc330en_US
dc.subject.keywordcost-effectiveness analysisen_US
dc.subject.keywordhormone replacement therapyen_US
dc.subject.keywordMarkov modelen_US
dc.subject.stwFrauenen_US
dc.subject.stwPharmazeutisches Produkten_US
dc.subject.stwKosten-Nutzen-Analyseen_US
dc.subject.stwMarkovscher Prozessen_US
dc.subject.stwSchwedenen_US
dc.subject.stwHormonpräparaten_US
dc.titleA reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomised controlled trialen_US
dc.typeWorking Paperen_US
dc.identifier.ppn476103010en_US
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen_US

Files in This Item:
File
Size
290.27 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.